(Q54449615)

30 May 2018

title

MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure. (English)

1 reference

30 May 2018

0 references

S A Rubin

1

1 reference

30 May 2018

L Tabak

series ordinal

2

1 reference

30 May 2018

language of work or name

English

0 references

publication date

1 June 1985

1 reference

30 May 2018

Journal of the American College of Cardiology

published in

1 reference

30 May 2018

volume

5

1 reference

30 May 2018

issue

6

1 reference

30 May 2018

page(s)

1422-1427

1 reference

30 May 2018

The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2885%2980359-4

7 January 2021

Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2885%2980359-4

7 January 2021

Metabolic assessment of exercise in chronic heart failure patients treated with short-term vasodilators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2885%2980359-4

7 January 2021

Arterial oxygenation and arterial oxygen transport in chronic myocardial failure at rest, during exercise and after hydralazine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2885%2980359-4

7 January 2021

Accuracy of cardiac output, oxygen uptake, and arteriovenous oxygen difference at rest, during exercise, and after vasodilator therapy in patients with severe, chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2885%2980359-4

7 January 2021

Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2885%2980359-4

7 January 2021

Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2885%2980359-4

7 January 2021

Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2885%2980359-4

7 January 2021

Intravenous and oral MDL 17043 (A new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2885%2980359-4

7 January 2021

Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2885%2980359-4

7 January 2021

10.1016/S0735-1097(85)80359-4

Identifiers

DOI

1 reference

30 May 2018

1 reference

30 May 2018